Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin's lymphoma (NHL).

Spaepen, K; Stroobants, Sigrid; Dupont, Patrick; Vanderberghe, P; Thomas, Jonathan; de Groot, T; Balzarini, Jan; De Wolf-Peeters, C.; Mortelmans, L; Verhoef, G.

Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin's lymphoma (NHL).

Spaepen, K

;

Stroobants, Sigrid

;

Dupont, Patrick

;

Vanderberghe, P

;

Verhoef, G.

;et.al.

(2001)

Files

No attached file found for this publication.

Details

Authors

Spaepen, K
Author
Stroobants, SigridUCLouvain
Author
Dupont, PatrickDepartment of Nuclear Medicine, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, BELGIQUE
Author
Vanderberghe, P
Author
Thomas, JonathanUCLouvain
Author
Verhoef, G.
Author

Affiliations

UCLouvain

Citations

APA
Chicago
FWB

Spaepen, K., Stroobants, S., Dupont, P., Vanderberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2001). Early restaging positron emmision tomography (PET) with 18F-fluorodeoxyglucose ((18)FDG) predicts outcome in patients with aggressive non Hodgkin’s lymphoma (NHL). Blood, 98(11), 726A-726A. (Original work published 2001)